We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.
- Authors
Mallett, Andrew; Tang, Wen; Clayton, Philip A.; Stevenson, Sarah; McDonald, Stephen P.; Hawley, Carmel M.; Badve, Sunil V.; Boudville, Neil; Brown, Fiona G.; Campbell, Scott B.; Johnson, David W.
- Abstract
Background Alport syndrome is a rare inheritable renal disease. Clinical outcomes for patients progressing to end-stage kidney disease (ESKD) are not well described. Methods This study aimed to investigate the characteristics and clinical outcomes of patients from Australia and New Zealand commencing renal replacement therapy (RRT) for ESKD due to Alport syndrome between 1965 and 1995 (early cohort) and between 1996 and 2010 (contemporary cohort) compared with propensity score-matched, RRT-treated, non-Alport ESKD controls. Results A total of 58 422 patients started RRT during this period of which 296 (0.5%) patients had Alport ESKD. In the early cohort, Alport ESKD was associated with superior dialysis patient survival [adjusted hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.20–0.83, P = 0.01], renal allograft survival (HR: 0.74, 95% CI: 0.54–1.01, P = 0.05) and renal transplant patient survival (HR: 0.43, 95% CI: 0.28–0.66, P < 0.001) compared with controls. In the contemporary cohort, no differences were observed between the two groups for dialysis patient survival (HR: 1.42, 95% CI: 0.65–3.11, P = 0.38), renal allograft survival (HR: 1.01, 95% CI: 0.57–1.79, P = 0.98) or renal transplant patient survival (HR: 0.67, 95% CI: 0.26–1.73, P = 0.41). One Alport patient (0.4%) had post-transplant anti-glomerular basement membrane (anti-GBM) disease. Four female and 41 male Alport patients became parents on RRT with generally good neonatal outcomes. Conclusion Alport syndrome patients experienced comparable dialysis and renal transplant outcomes to matched non-Alport ESKD controls in the contemporary cohort due to relatively greater improvements in outcomes for non-Alport ESKD patients over time. Post-transplant anti-GBM disease was rare.
- Subjects
CHRONIC kidney failure; ALPORT syndrome; HEALTH outcome assessment; HEMODIALYSIS; KIDNEY transplantation; GENETIC disorders
- Publication
Nephrology Dialysis Transplantation, 2014, Vol 29, Issue 12, p2277
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfu254